Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Dec 12, 2023
Date Accepted: Mar 21, 2024

The final, peer-reviewed published version of this preprint can be found here:

Mi Sleep Coach Mobile App to Address Insomnia Symptoms Among Cancer Survivors: Single-Arm Feasibility Study

Arring N, Barton DL, Lafferty C, Cox B, Conroy DA, An L

Mi Sleep Coach Mobile App to Address Insomnia Symptoms Among Cancer Survivors: Single-Arm Feasibility Study

JMIR Form Res 2024;8:e55402

DOI: 10.2196/55402

PMID: 38669678

PMCID: 11087861

The Mi Sleep Coach Mobile App to Address Insomnia Symptoms Among Cancer Survivors: A Pilot Feasibility Study

  • Noel Arring; 
  • Debra L. Barton; 
  • Carolyn Lafferty; 
  • Bryana Cox; 
  • Deidre A. Conroy; 
  • Larry An

ABSTRACT

Background:

Cancer survivors reported sleep disturbances are more than three times higher than the general population. The causes of sleep disturbance among survivors are many and multifaceted, including anxiety and fear related to cancer diagnosis and treatments. Cognitive behavioral therapy for insomnia (CBT-I) is considered a first-line treatment for insomnia; However, a lack of access to trained professionals and limited insurance coverage for CBT-I services has limited patient access to these effective treatments. To address the critical need for accessible and efficacious CBT-I for cancer survivors, the Mi Sleep Coach app adapted CBT-I for delivery as a self-directed mobile health application for cancer survivors.

Objective:

This pilot and feasibility study assessed the adherence, attrition, usefulness, and satisfaction of the Mi Sleep Coach app as an intervention for insomnia.

Methods:

This pilot and feasibility study assessed the adherence, attrition, usefulness, and satisfaction of the Mi Sleep Coach app as an intervention for insomnia.

Results:

Thirty participants were enrolled, with 100% completing the study and providing data through week 7. Nine out of 10 app features were found to be useful by 80-93% of participants. Twenty-seven (90%) of the 30 participants were satisfied with the Mi Sleep Coach app and 28 (93%) of the 30 participants would recommend the use of the Mi Sleep Coach app for those with insomnia. The mean change score on the Insomnia Severity Index of 8.1 was a significant decrease from baseline (18.5, SD 4.6) to Week 7 (10.4, SD 4.2, p=<.001, Cohen’s d =1.5). Twenty-five (83%) participants scored in the moderate (15-21, n=19) or severe (22-28, n=6) insomnia range at baseline. At Week 7, four patients (13%) scored in the moderate (n=4) or severe (n=0) range. Both prescription and over-the-counter sleep medication use decreased from baseline to Week 7.

Conclusions:

The Mi Sleep Coach app is a promising intervention for cancer-related insomnia; further clinical trials are warranted. The Mi Sleep Coach app is specifically designed to help cancer survivors sleep better. If proven to significantly decrease insomnia in cancer survivors in future clinical trials, this intervention could enable more cancer survivors to receive CBT-I. Clinical Trial: NCT04827459


 Citation

Please cite as:

Arring N, Barton DL, Lafferty C, Cox B, Conroy DA, An L

Mi Sleep Coach Mobile App to Address Insomnia Symptoms Among Cancer Survivors: Single-Arm Feasibility Study

JMIR Form Res 2024;8:e55402

DOI: 10.2196/55402

PMID: 38669678

PMCID: 11087861

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.